Ex Vivo Gene Therapy to Produce Bone Using Different Cell Types
Authors:
- Patrick BoschPBPatrick Bosch
- Joon Y. LeeJLJoon Y. Lee
- Dalip PelinkovicDPDalip Pelinkovic
- Steve C. GhivizzaniSGSteve C. Ghivizzani
- Janey WhalenJWJaney Whalen
- Christopher NiyibiziCNChristopher Niyibizi
- Johnny HuardJHJohnny Huard
- 1 September 2000
- journal article
- research article
- Published by Wolters Kluwer Health in Clinical Orthopaedics and Related Research
- Vol. 378 (378) , 290-305
Abstract
Gene therapy and tissue engineering promise to revolutionize orthopaedic surgery. This study comprehensively compares five different cell types in ex vivo gene therapy to produce bone. The cell types include a bone marrow stromal cell line, primary muscle derived cells, primary bone marrow stromal cells, primary articular chondrocytes, and primary fibroblasts. After transduction by an adenovirus encoding for bone morphogenetic protein-2, all of the cell types were capable of secreting bone morphogenetic protein-2. However, the bone marrow stromal cell line and muscle derived cells showed more responsiveness to recombinant human bone morphogenetic protein-2 than did the other cell types. In vivo injection of each of the cell populations transduced to secrete bone morphogenetic protein-2 resulted in bone formation. Radiographic and histologic analyses corroborated the in vitro data regarding bone morphogenetic protein-2 secretion and cellular osteocompetence. This study showed the feasibility of using primary bone marrow stromal cells, primary muscle derived cells, primary articular chondrocytes, primary fibroblasts, and an osteogenesis imperfecta stromal cell line in ex vivo gene therapy to produce bone. The study also showed the advantages and disadvantages inherent in using each cell type.Keywords
This publication has 36 references indexed in Scilit:
- Percutaneous spinal fusion using bone morphogenetic protein-2 gene therapyJournal of Neurosurgery: Spine, 1999
- Effect of rhBMP-2 on the osteogenic potential of bone marrow stromal cells from an osteogenesis imperfecta mouse (oim)Bone, 1997
- Recombinant bone morphogenetic protein (BMP)‐2 regulates costochondral growth plate chondrocytes and induces expression of BMP‐2 and BMP‐4 in a cell maturation‐dependent mannerJournal of Orthopaedic Research, 1997
- Stimulation of new bone formation by direct transfer of osteogenic plasmid genes.Proceedings of the National Academy of Sciences, 1996
- Possible orthopaedic applications of gene therapy.Journal of Bone and Joint Surgery, 1995
- Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage [published erratum appears in J Cell Biol 1995 Feb;128(4):following 713]Journal of Cell Biology, 1994
- Characterization of cells with osteogenic potential from human marrowBone, 1992
- Mesenchymal stem cellsJournal of Orthopaedic Research, 1991
- Fibrodysplasia ossificans progressiva: A clue from the fly?Calcified Tissue International, 1990
- Behavior of Articular Chondrocytes in Cell CultureClinical Orthopaedics and Related Research, 1971